PSMB7 and plasma cell myeloma: The same study described an increased aROR of 1.41 (95% CI 1.15–1.74) for the proteasome inhibitor bortezomib, used in treatment for multiple myeloma, which is associated with the target gene PSMB7. Similar results are reported for the other proteasome inhibitors ixazomib and bortezomib from disproportionality analyses from other pharmacovigilance databases.88